Filter...

AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaHumanitiesInformation ScienceHealth Care

Select a category...

EpirubicinCyclophosphamideTaxoidsAntineoplastic Combined Chemotherapy ProtocolsDrug Administration SchedulePaclitaxelDoxorubicinBreast NeoplasmsFluorouracilAntibiotics, AntineoplasticTreatment OutcomeAntineoplastic Agents, PhytogenicVincristineCisplatinAntineoplastic Agents, AlkylatingDisease-Free SurvivalAntineoplastic AgentsPhosphoramide MustardsDose-Response Relationship, DrugChemotherapy, AdjuvantPrednisoneCombined Modality TherapyMethotrexateNeutropeniaGranulocyte Colony-Stimulating FactorInfusions, IntravenousLeukopeniaSurvival AnalysisDeoxycytidineSurvival RateNeoadjuvant TherapyEtoposideVinblastineMaximum Tolerated DoseNeoplasm MetastasisToxicity TestsRemission InductionNeoplasm StagingAnthracyclinesImmunosuppressive AgentsLung NeoplasmsAlopeciaIfosfamideThiotepaCarboplatinMitoxantronePulse Therapy, DrugRazoxaneHematologic DiseasesTime FactorsDrug Resistance, NeoplasmAdenocarcinomaBusulfanPrednisoloneVomitingFollow-Up StudiesNeoplasmsNauseaLymphoma, Non-HodgkinDrug Therapy, CombinationProstatic NeoplasmsAdministration, OralAntibodies, Monoclonal, Murine-DerivedNeoplasm Recurrence, LocalStomach NeoplasmsAntibodies, Monoclonal, HumanizedDisease ProgressionReceptor, erbB-2Carcinoma, Non-Small-Cell LungDrug SynergismDrug EvaluationVidarabineStomatitisBone Marrow TransplantationHematopoietic Stem Cell TransplantationAntibodies, MonoclonalLymphatic MetastasisMethylprednisoloneProspective StudiesPrognosisEstramustineInjections, IntravenousTransplantation, AutologousToxicity Tests, AcuteFeasibility StudiesCell Line, TumorAstheniaBone NeoplasmsWhole-Body IrradiationKaplan-Meier EstimateArea Under CurveBiotransformationCystitisCarmustineBleomycinMelphalanTegafurOvarian NeoplasmsAdministration, MetronomicMastectomy, Radical

DoxorubicinAdjuvant chemotherapyAnthracycline-cyclophosphamideFluorouracilNeoadjuvantTrastuzumabCarboplatinTaxotereLiver toxicityPulmonary toxicityUnacceptable toxicityRegimensAcuteCarcinogenicityRegimenCardiacMechanismManifestsCombinationOncologySignificantly higherPeripheralOverall survivalCancerSeverePregnancyAdverseHigherCellsResultsResponse

Doxorubicin17

• A cohort of 85 Chinese breast cancer patients who received adjuvant chemotherapy with doxorubicin and cyclophosphamide was found to have a significantly higher incidence of grade 3 (n=44, 52%) and grade 4 (n=21, 25%) neutropenia when compared with an historic Western cohort. (nih.gov)
• FAC (or CAF): 5-fluorouracil, doxorubicin, cyclophosphamide. (wikipedia.org)
• AC (or CA): Adriamycin (doxorubicin) and cyclophosphamide. (wikipedia.org)
• TAC: Taxotere (docetaxel), Adriamycin (doxorubicin), and cyclophosphamide. (wikipedia.org)
• It has been shown that the breast cancer is sensitive to the most anti-tumour medicines, especially to doxorubicin and epirubicin (efficacy in 40-50% of patients with the metastatic breast cancer), methotrexate (efficacy in 35% of patients), fluorouracil and tegafur (efficacy in 25-34% of patients). (crimsonpublishers.com)
• For using in the neoadjuvant regimen NCCN primarily recommends compactedozorozhimas AC (doxorubicin+cyclophosphamide) with sequential using of paclitaxel or TC (docetaxel in combination with cyclophosphamide). (crimsonpublishers.com)
• C167080 SEER Rx Interactive Antineoplastic Drugs Database-Regimen C161966 ACFTOR-BCG Regimen FAC-BCG A chemotherapy regimen consisting of tegafur, doxorubicin, cyclophosphamide, and Bacillus Calmette-Guerin (BCG) that may be used in the treatment of breast cancer. (nih.gov)
• C167080 SEER Rx Interactive Antineoplastic Drugs Database-Regimen C63427 AC-T Regimen AC-T A chemotherapy regimen consisting of cyclophosphamide and doxorubicin followed by paclitaxel, used as a neoadjuvant or adjuvant treatment for breast cancer. (nih.gov)
• C167080 SEER Rx Interactive Antineoplastic Drugs Database-Regimen C63446 ACVBP Regimen ACVBP A regimen consisting of doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone used to treat aggressive forms of non-Hodgkin lymphoma. (nih.gov)
• C167080 SEER Rx Interactive Antineoplastic Drugs Database-Regimen C161920 ADOC Regimen ADOC A chemotherapy regimen consisting of cisplatin, doxorubicin, vincristine, and cyclophosphamide for the treatment of thymic carcinoma. (nih.gov)
• C167080 SEER Rx Interactive Antineoplastic Drugs Database-Regimen C161924 ASHAP Alternating with M-BACOS Regimen ASHAP/M-BACOS A chemotherapy regimen consisting of doxorubicin, methylprednisolone, cytarabine, and cisplatin (ASHAP) alternating with methotrexate, leucovorin, doxorubicin, vincristine, bleomycin, cyclophosphamide, and methylprednisolone for the treatment of non-Hodgkin lymphoma. (nih.gov)
• This is a post hoc subanalysis of a prospective non-interventional study in 1,197 patients with breast cancer receiving up to 3 cycles of doxorubicin or epirubicin plus cyclophosphamide and NEPA. (karger.com)
• Other chemotherapeutic agents with significant activity against SCLC include the alkylating agents ifosfamide and cyclophosphamide , doxorubicin , the taxanes paclitaxel and docetaxel , and vincristine . (trc-p.nl)
• The combination cyclophosphamide, doxorubicin and etoposide (CDE) was very popular in the past, but the toxicity was higher than the more recent agents which show at least the same efficacy. (trc-p.nl)
• Biocon Biologics Ltd), BT-ON013 - following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel - in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. (who.int)
• INTRODUCTION - The anthracyclines ( doxorubicin [liposomal and unencapsulated], daunorubicin , idarubicin , epirubicin ) and the anthraquinone mitoxantrone (referred to hereafter as "anthracyclines") are chemotherapeutic agents that cause cardiotoxicity. (medilib.ir)
• In total, 1174 adult patients with previously untreated, non-metastatic, centrally confirmed TNBC (stage T1c N1-2 or T2-4 N0-2 per AJCC) were randomised 2:1 to neoadjuvant pembrolizumab 200 mg Q3W or placebo, both given with 4 cycles of paclitaxel plus carboplatin, followed by 4 cycles of doxorubicin or epirubicin plus cyclophosphamide. (congressupdateoncology.be)

Adjuvant chemotherapy3

• The following is a list of some of the commonly used adjuvant chemotherapy for breast cancer: CMF: cyclophosphamide, methotrexate, and 5-fluorouracil. (wikipedia.org)
• Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). (cdc.gov)
• in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. (medicines.org.uk)

Anthracycline-cyclophosphamide3

• Here, we report on the effects on QoL, effectiveness, and tolerability of NEPA in patients with breast cancer exposed to anthracycline-cyclophosphamide (AC)-based Ctx. (karger.com)
• The greatest benefit was seen in patients treated with anthracycline-cyclophosphamide, methotrexate, 5-fluorouracil (CMF) rather than CMF. (sath.nhs.uk)
• Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer - GBG69. (jamanetwork.com)

Fluorouracil5

• FEC: 5-fluorouracil, epirubicin and cyclophosphamide. (wikipedia.org)
• C167080 SEER Rx Interactive Antineoplastic Drugs Database-Regimen C9511 AcFuCy Regimen ACFUCY A chemotherapy regimen consisting of dactinomycin, 5-fluorouracil, and cyclophosphamide for the treatment of ovarian cancer. (nih.gov)
• C167080 SEER Rx Interactive Antineoplastic Drugs Database-Regimen C10058 Altretamine/Cisplatin/Cyclophosphamide/Fluorouracil Regimen CHEX-UP A regimen consisting of altretamine, cisplatin, cyclophosphamide and fluorouracil that can be used for the treatment of ovarian cancer. (nih.gov)
• Two postmenopausal women with breast cancer developed acute confusion and seizures, less than 24 hours after the first cycle of neoadjuvant chemotherapy with fluorouracil, epirubicin and low-dose cyclophosphamide. (sath.nhs.uk)
• Background Neoadjuvant chemotherapy (NAC) with taxanes accompanied by fluorouracil epirubicin and cyclophosphamide (FEC) and concurrent trastuzumab is a potent program for HER2 over-expressing breasts cancer. (healthdisparitiesks.org)

Neoadjuvant1

• We were able to show this in the TECHNO [Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant] Study. (medscape.com)

Trastuzumab5

• We assessed patients according to HER2 status and if they were HER2-positive by local pathology, patients were given chemotherapy with epirubicin, cyclophosphamide (EC) 4 cycles, followed by docetaxel 4 cycles either in combination with trastuzumab or in combination with lapatinib. (medscape.com)
• Yes, but this is something that we have already explored in the GeparQuattro study, in which we treated 450 patients with this exact combination of trastuzumab with EC followed by docetaxel, so the new approach was to give lapatinib in combination with epirubicin. (medscape.com)
• There is also a metastatic trial where trastuzumab was given in combination with epirubicin. (medscape.com)
• In a further in-depth study, the results of a combination chemotherapy regimen using trastuzumab with docetaxel or taxane resulted in overall survival of patients that was higher than that obtained using chemotherapy alone [ 5 ] . (encyclopedia.pub)
• with HER2-positive Raddeanoside R8 invasive breast cancer received either docetaxel or paclitaxel accompanied by FEC using the concomitant administration of trastuzumab. (healthdisparitiesks.org)

Carboplatin2

• Other variants of the priority regimens are TSN (docetaxel+carboplatin+herceptin) or TSN + pertuzumab [6]. (crimsonpublishers.com)
• Carboplatin is frequently substituted for cisplatin because of its more favourable toxicity profile. (trc-p.nl)

Taxotere1

• Taxotere, also known as docetaxel, is a chemotherapy drug that doctors prescribe to treat several different cancers - most commonly, breast cancer. (chronic-pain.org)

Liver toxicity2

• In addition, the drug carries a black box warning that includes five complications that can be severe or fatal: toxic death, low blood cell counts, liver toxicity, fluid retention and hypersensitivity reactions. (chronic-pain.org)
• This medication can cause liver toxicity, which your oncology care team may monitor for using blood tests called liver function tests. (oncolink.org)

Pulmonary toxicity3

• Pulmonary Toxicity: Discontinue HERCEPTIN HYLECTA for anaphylaxis, angioedema, interstitial pneumonitis or acute respiratory distress syndrome. (nih.gov)
• HERCEPTIN HYLECTA administration can result in serious and fatal pulmonary toxicity. (nih.gov)
• See "Initial treatment of advanced (stage III-IV) classic Hodgkin lymphoma", section on 'Cardiac and pulmonary toxicity' . (medilib.ir)

Unacceptable toxicity1

• After definitive surgery, patients received adjuvant pembrolizumab or placebo for nine cycles or until recurrence or unacceptable toxicity. (congressupdateoncology.be)

Regimens1

• However, two-drug regimens substituting a topoisomerase inhibitor ( irinotecan , or epirubicin ) for etoposide are reasonable alternatives. (trc-p.nl)

Acute1

• Myelosuppression is the acute dose-limiting toxicity for most nonspecific chemotherapy. (basicmedicalkey.com)

Carcinogenicity1

• Although NIOSH hazardous drug evaluation includes consideration of carcinogenicity and geno- toxicity, this evaluation is tailored to identify and evaluate data from human toxicity profiles, animal studies and in vitro studies unique to evaluating therapeutic agents. (cdc.gov)

Regimen1

• She was given a TEC regimen (docetaxel 75 mg/m(2), epirubicin 75 mg/m(2), and cyclophosphamide 600 mg/m(2) every 3 weeks) for one cycle but showed no objective response. (pimpathway.com)

Cardiac1

• We did not see any of the cardiac toxicity reported in the initial pivotal metastatic trials. (medscape.com)

Mechanism2

• Either increases toxicity of the other by unknown mechanism. (medscape.com)
• Understanding the mechanism of toxicities can lead to more effective prevention and treatment of these toxicities. (basicmedicalkey.com)

Manifests1

• Most commonly, anthracycline toxicity manifests as a temporary or permanent reduction in left ventricular (LV) function. (medilib.ir)

Combination1

• in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. (medicines.org.uk)

Oncology1

• A systematic approach to diagnosis and treatment of hyponatraemia in an oncology patient requires awareness of toxicities of systemic anticancer agents. (sath.nhs.uk)

Significantly higher1

• The rate of RAM discontinuation for ≤ 6M due to anti-VEGF toxicities was significantly higher in the prior BEV treatment group compared with that in the no prior BEV treatment group (18% vs. 6%, P = 0.02). (kindai.ac.jp)

Peripheral1

• Ile105/Ile105 homozygotes) had a higher risk of developing docetaxel-induced peripheral neuropathy (DIPN), particularly grade 2 or higher. (snpedia.com)

Overall survival1

• Its escalated anti-VEGF toxicity may negatively impact the overall survival. (kindai.ac.jp)

Cancer6

• The chemotherapy resistance and toxicity of chemotherapy are major problems in breast cancer treatment. (nih.gov)
• In this study, we analyzed possible impact of 8 genetic variants of fibroblast growth factor receptor1-4 (FGFR1-4) on the treatment response and toxicities in 211 breast cancer patients. (nih.gov)
• The FGFR4 rs1966265 and FGFR2 rs2981578 contributed to clinical outcome of breast cancer treated with docetaxel-epirubicin-cyclophosphamide (CET)-based chemotherapy. (nih.gov)
• Thus, paclitaxel is effective in 32-62% of patients, docetaxel in 50-75%, vinorelbin in 41-51%, topotecan in 36%, mitoxantrone in 20-35% of patients with the metastatic breast cancer in the first line [3]. (crimsonpublishers.com)
• A relatively small study of 58 patients with different types of cancer receiving docetaxel concluded that rs1695 (A;A) homozygotes (i.e. (snpedia.com)
• The new developments in the treatment of breast cancer include targeted therapy, which has the advantages of accurate positioning, high efficiency, and low toxicity, as compared to surgery, radiotherapy, and chemotherapy. (encyclopedia.pub)

Severe1

• Taxane scheduling influenced the type of severe toxicities. (biomedcentral.com)

Pregnancy1

• Embryo-Fetal Toxicity: Exposure to HERCEPTIN HYLECTA during pregnancy can result in oligohydramnios, in some cases complicated by pulmonary hypoplasia and neonatal death. (nih.gov)

Adverse1

• Aprepitant was discontinued and both women were successfully re-challenged with full dose cyclophosphamide in an outpatient setting with no subsequent adverse events. (sath.nhs.uk)

Higher1

• When compared to Caucasian patients, the higher myelotoxicity in our patients may be related to ethnic variation in susceptibility to chemotherapy-related toxicity, lower body mass index with higher percentage of body fat composition, and the popular practice of concurrent alternative medicine during chemotherapy. (nih.gov)

Cells1

• Not all normal dividing cells escape however, a fact that contributes to the toxicity of these drugs. (cancerquest.org)

Results1

• Combined therapies Combining, for example, non-drug treatments with localized chemotherapy to limit toxicity and achieve better results. (wikipedia.org)

Response1

• Sequential single-agent chemotherapy is the next therapeutic option but is associated with declining response rates and disease control and increased toxicity. (medscape.com)